Coya Therapeutics Inc — Quarterly Cash Flow (NASDAQ:COYA) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics

Quarterly Annual

Total assets 44.35 M38.4 M33.45 M32.04 M49.95 M Total liabilities 4.77 M5.04 M5.14 M4.76 M6.92 M Total equity 39.58 M33.37 M28.31 M27.28 M43.03 M Total liabilities & shareholders' equities 44.35 M38.4 M33.45 M32.04 M49.95 M Total debt ————— Net debt —————

Nouvelles

3 Best Stocks to Buy Today, 3/23/2026, According to Top Analysts - TipRanks.com

Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock?

H.C. Wainwright maintient sa recommandation d’achat sur Coya Therapeutics avec un objectif de 18€

H.C. Wainwright reiterates Buy rating on Coya Therapeutics stock with $18 target

Coya Therapeutics obtient 11,1 millions $ via un placement privé

Coya Therapeutics secures $11.1 million in private placement

Coya Therapeutics avance dans ses essais cliniques sur la SLA et la DFT en 2026

Coya Therapeutics advances ALS and FTD clinical trials in 2026

H.C. Wainwright maintient sa recommandation d’achat sur Coya Therapeutics avec un objectif de 18$

H.C. Wainwright reiterates Buy rating on Coya Therapeutics stock at $18

Tracking David Einhorn’s Greenlight Capital Portfolio – Q3 2025 Update (NYSE:GRBK)

H.C. Wainwright maintient sa recommandation d’achat sur l’action Coya Therapeutics